Roche, obesity and Zealand

Roche, Zealand Pharma Strike $5.3 Billion Weight-Loss Therapy Deal
Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to co-develop a weight-loss treatment.
Roche pairs with Zealand Pharma on obesity drug candidate
Roche has entered an exclusive collaboration and licensing agreement with Danish obesity drug maker Zealand Pharma to co-develop petrelintide as an obesity therapy drug, the Swiss company said on Wednesday.
Roche, Zealand Pharma ink pact to co-develop, co-commercialise petrelintide as foundational therapy for obesity
Basel: Roche has announced that it has entered into an exclusive collaboration and licensing agreement with Zealand Pharma. Under the terms of this agreement, the two companies will collaborate
Zealand Pharma to pay $350M to Roche in petrelintide collaboration, license pact
Zealand Pharma (ZLDPF) and Roche (RHHBY) entered a collaboration and license agreement to co-develop and co-commercialize petrelintide as a
Zealand and Roche strike $5.3bn obesity treatment deal
The two companies will work together on Zealand’s amylin analogue petrelintide as a monotherapy and in combination therapies.
Roche, Zealand Launch Up-to-$5.3B Obesity Collaboration
Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor agonists but without the side effects associated with GLP-1 drugs.
Hims & Hers, Zealand, and Roche fall: Why weight loss drug stocks are down today
Several weight loss drug stocks are sliding today as pharmaceutical companies battle for dominance in the booming GLP-1 market — which is projected to hit $105 billion by 2030, according to Morgan Stanley (MS) analysts.
Roche builds in obesity with $5.3bn Zealand licensing deal
Roche has parted with $1.4 billion upfront to secure rights to an obesity candidate developed by Zealand Pharma, taking its tally of weight-loss candidates in clinical development to five.
Roche secures Zealand obesity drug candidate for up to $5.3 billion
Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming weight-loss market.
Zealand Pharma Shares Leap After Weight-Loss Licensing Deal With Roche
Zealand Pharma shares rose sharply after the Danish pharmaceutical company struck a licensing and collaboration deal of up to $5.3 billion with Roche. Shares in Zealand were up 25% at 609 Danish kroner in European morning trading Wednesday,
Roche signs biggest-ever obesity drug deal
Roche has signed the biggest-ever obesity drug deal with a $5.3bn licensing agreement for a next-generation treatment from Danish biotech Zealand Pharma. The Swiss pharmaceutical company will collaborate with Zealand on petrelintide,
Roche And Zealand Team Up To Develop Petrelintide
Roche & Zealand join forces on petrelintide, advancing obesity treatments with innovative amylin analogs. Find out why this ...
Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.
Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to ...
Fierce Biotech4d
Roche pads out obesity pipeline, paying Zealand $1.6B upfront to codevelop amylin asset
Roche is paying $1.65 billion in confirmed upfront fees to add to its burgeoning obesity pipelin | Roche is paying $1.65 ...
Roche Targets Weight-Loss Drug Market Dominated by Novo Nordisk, Eli Lilly
Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...